ClinicalTrials.gg
CompletedNCT04835337Updated Sep 24, 2024

The Health Benefits of Indoor Air Filtration Among Children

An interventional study of Air Purifiers and Sham Air Purifiers in Protective Effect of Air Purifier on Children's Health, sponsored by Tiantian Li. Completed at 1 site in China. Open to participants aged 10 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Tiantian Li · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
10 Years to 12 Years
Sex
All
01

Study summary

This study aims to explore the health benefits of air purifier on the impact of air pollutants on children's health.

Read the detailed description

From April 2021 to December 2021, researchers conduct a randomized double-blind crossover trial on about 100 healthy children in Jiaozuo City, Henan Province. The children are divided into two groups according to their classes and alternated the use of true or sham purifiers devices, including air purifiers and fresh air ventilation. Air purifiers are installed in the classroom and bedrooms of the children. Fresh air ventilation is installed in the classroom. A total of 4 epidemiological surveys are conducted on the subjects, with an interval of 60 days or more. All participants and research staffs were blinded to the group assignment. In addition, air pollutant exposure monitoring, questionnaire surveys, physical examinations, and biological sample collection are conducted on the research subjects each time. The biological samples are further tested for the concentration levels of related biomarkers such as the respiratory system, cardiovascular system, metabolic system, and nervous system. Furthermore, comprehensive evaluation of children's behavioral ability is also carried out. Ambient PM2.5 and indoor PM2.5 exposure concentrations are monitored in the study.

02

Conditions studied

  • Protective Effect of Air Purifier on Children's Health
03

In context

Lead sponsor

Tiantian Li is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 10 ≤ 12 years old
  • Volunteer to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Current and past medical history, including asthma, childhood diabetes, childhood hypertension, behavior-related diseases
  • Students who plan to transfer or move within six months
  • Unable to cooperate with follow-up
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Air purifier

    Participants in this group receive an intervention of real air purifiers placed in the indoor environment.

    Behavioral: Air Purifiers

  • Sham comparator
    Control

    Participants in this group receive an intervention of sham air purifiers, we just remove the filter in the purifiers, and the other treatments are the same as the real purification group.

    Behavioral: Sham Air Purifiers

Interventions

  • BehavioralAir Purifiers

    Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.

  • BehavioralSham Air Purifiers

    The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.

06

What researchers measure

Primary outcomes

  1. Changes of FEV1

    The forced expiratory volume in 1 s (FEV1) is measured using a smart spirometer (Model A1, BreathHome, China) supervised by professional medical staff. Before the pulmonary function test, subjects will practice several times by themselves. During the examination, each subject stands and clamps the nose clip, and repeats the test, with the best result as the criterion. FEV1 reflect pulmonary function.

    Time frame: Baseline and at the end of each 60 days intervention period

  2. Changes of FVC

    The forced vital capacity (FVC) is measured using spirometer (Model A1, BreathHome, China). FVC reflects the expiratory resistance of large airways.

    Time frame: Baseline and at the end of each 60 days intervention period

  3. Changes of FEV1/FVC ratio

    The FEV1/FVC ratio is measured using smart spirometer (Model A1, BreathHome, China). FEV1/FVC ratio reflects the status of airway obstruction.

    Time frame: Baseline and at the end of each 60 days intervention period

  4. Changes of PEF

    The peak expiratory flow (PEF) is measured using smart spirometer (Model A1, BreathHome, China). PEF reflects airway patency and respiratory muscle strength.

    Time frame: Baseline and at the end of each 60 days intervention period

  5. Changes of FEF25-75%

    The forced expiratory flow at 25-75% of FVC (FEF25-75%) is measured using smart spirometer (Model A1, BreathHome, China). FEF25-75% reflects the small airway obstruction.

    Time frame: Baseline and at the end of each 60 days intervention period

  6. Changes of MEF75%

    The maximal expiratory flow at 75% of FVC (MEF75%) is measured using smart spirometer (Model A1, BreathHome, China). MEF75% reflects the terminal stage of expiratory flow rate.

    Time frame: Baseline and at the end of each 60 days intervention period

  7. Changes of MEF50%

    The maximal expiratory flow at 50% of FVC (MEF50%) is measured using smart spirometer (Model A1, BreathHome, China). MEF50% reflects the interim stage of expiratory flow rate.

    Time frame: Baseline and at the end of each 60 days intervention period

  8. Changes of MEF25%

    The maximal expiratory flow at 25% of FVC (MEF25%) is measured using smart spirometer (Model A1, BreathHome, China). MEF25% reflects the early stage of expiratory flow rate.

    Time frame: Baseline and at the end of each 60 days intervention period

  9. Changes of FeNO

    Use NIOX VERO Sensor to measure fractional exhaled nitric oxide (FeNO) as a biomarker for airway inflammation level. After deep breathing, the subjects gently inhaled into the device. The instrument showed FeNO level of the subjects.

    Time frame: Baseline and at the end of each 60 days intervention period

  10. Changes of FeCO

    Use Pico Smokerlyzer to measure fractional exhaled carbon monoxide (FeCO). After deep breathing, the subjects held their breath for 15 seconds and then gently inhaled into the device. The instrument showed FeCO level and the estimated value of carboxyhemoglobin in blood.

    Time frame: Baseline and at the end of each 60 days intervention period

  11. Changes of Blood Pressure

    The professional staffs wrap the BP cuff around the left upper arm of children to measure BP using the Omron electronic sphygmomanometers (OMROM, J751). BP is measured at 2-minute intervals, with a total of three measurements taken. If the difference of BP values between the last two measurements exceeds 5 mmHg, additional measurements are performed. Each child is allowed to measure BP at least three times and up to five times. The BP indicators includes SBP, DBP, MAP and PP.

    Time frame: Baseline and at the end of each 60 days intervention period

  12. Changes of heart rate variability

    The trained staffs conduct a 3-minute comprehensive assessment using the handheld electrocardiographic recorder-CarePatch (ECG-H01, Hangzhou Proton Technology Co., Ltd., China) to measured HRV. The time-domain indicators include standard deviation of all normal-to-normal intervals (SDNN), the root mean square of successive differences between adjacent normal cycles (rMSSD), the percentage of adjacent NN interval differences greater than 50 ms (pNN50); and the frequency-domain indicators include very low frequency (VLF), low frequency (LF), high frequency (HF), the ratio of LF to HF (LF/HF). To eliminate possible error, subjects are conducted by the same trained staff using the same instrument.

    Time frame: Baseline and at the end of each 60 days intervention period

  13. Changes of PR interval

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the interval of the beginning of the P wave to the beginning of the QRS complex (PR interval).

    Time frame: Baseline and at the end of each 60 days intervention period

  14. Changes of QRS duration

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the interval of the beginning of Q wave to the end of the S wave (QRS duration).

    Time frame: Baseline and at the end of each 60 days intervention period

  15. Changes of QT interval

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the interval from the onset of the QRS complex to the end of the T wave (QT interval).

    Time frame: Baseline and at the end of each 60 days intervention period

  16. Changes of QTc interval

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the QT correction for rate (QTc interval).

    Time frame: Baseline and at the end of each 60 days intervention period

  17. Changes of RV5

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the amplitude of the R-wave in lead V5 (RV5).

    Time frame: Baseline and at the end of each 60 days intervention period

  18. Changes of SV1

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the S-wave depth in lead V1 (SV1).

    Time frame: Baseline and at the end of each 60 days intervention period

  19. Changes of RV5+SV1

    The trained staff use a 12-lead electrocardiogram (ECG) monitor to measure the participants' the sum of the R-wave amplitude in lead V5 and the S-wave amplitude in lead V1(RV5+SV1).

    Time frame: Baseline and at the end of each 60 days intervention period

  20. Changes of academic performance

    The assessment of academic performance consists of standardised scores (maths, chinese and total) and the relative rank of the scores within grade. Standardised scores are converted from raw scores (with minimum value of 0 and maximum of 100) according to the number of exams and classes, indicating the position of the sample value in the normal distribution curve, with higher value showing better outcome. Rankings are converted from place rankings of raw values, with lower value showing better outcome.

    Time frame: Baseline and at the end of each 60 days intervention period

Secondary outcomes

  1. Changes of CRP

    Detect the concentration of C-reactive protein in blood sample to examine the different level of inflammation between the group of intervention and control.

    Time frame: Baseline and at the end of each 60 days intervention period

  2. Changes of 8-OHdG

    Detect the concentration of 8-hydroxydeoxyguanosine (8-OHdG) in urine sample as a marker of generalized, cellular oxidative stress to DNA.

    Time frame: Baseline and at the end of each 60 days intervention period

  3. Changes of metabolites in exhaled breath condensate

    Collect the exhaled breath condensate and identify the metabolites of exhaled breath condensate using Ultra-high performance liquid chromatography-tandem mass spectrometry.

    Time frame: Baseline and at the end of each 60 days intervention period

  4. Changes of the role of alertness

    Alertness can be measured by the Attention Network Test and reflects an individual's acquisition and maintenance of a state of alertness to a particular type of information or target.

    Time frame: Baseline and at the end of each 60 days intervention period

  5. Changes of the role of orientation

    Orientation can be measured by the Attention Network Test and reflects an individual's selective attention to externally useful information.

    Time frame: Baseline and at the end of each 60 days intervention period

  6. Changes of the role of conflict

    Conflict can be measured by the Attention Network Test and reflects an individual's ability to process conflicting information.

    Time frame: Baseline and at the end of each 60 days intervention period

  7. Changes of Wisconsin Card Sorting Test indicators

    WCST contains absolute indicators of cognitive executive functioning which include level of conceptualisation, persistence and set maintenance. The cognitive absolute indicators include conceptual thinking includes complete correct (TC), complete error (TE), non-persistent error (NPE), conceptual level response (CLR) and category completed (CC), persistence includes persistent response (PR) and persistent error (PE), and pooling maintenance includes inability to maintain pooling (FM).WCST percentage metrics are similar in meaning to the absolute metrics, and can be categorised into the level of conceptualisation and the Two dimensions of persistence. Cognitive percentage indicators include conceptual thinking consists of total correct percentage (%TC), total error percentage (%TE), non-persistent error percentage (%NPE), and conceptual level response percentage (%NPE); persistence consists of persistent response percentage (%PR) and persistent error percentage (%PE).

    Time frame: Baseline and at the end of each 60 days intervention period

  8. Changes of the position total number

    The position total number is the number of all position-related stimuli during the N-back test. The subjects need to remember how each position changed and judge whether a duplicate position stimulus appeared after N rounds.

    Time frame: Baseline and at the end of each 60 days intervention period

  9. Changes of the position number correct

    The position number correct is the number of times during the N-back test that the subjects were able to correctly judge whether or not a repeated position appeared in N rounds. A higher number correct indicates that the tester performed better in remembering and recognising the location.

    Time frame: Baseline and at the end of each 60 days intervention period

  10. Changes of the position percentage correct

    Changes of position percentage correct is the accuracy of the -N-back test subjects in position-related tasks, expressed as a percentage. It is calculated as (number of locations correct ÷ total number of location stimuli) × 100%. A high rate of correctness indicates that the subjects' accuracy in location memory is high.

    Time frame: Baseline and at the end of each 60 days intervention period

  11. Changes of the color total number

    The color total number is the number of all colour-related stimuli during the -N-back test. The subjects were required to remember the colour changes and determine whether a repeated colour stimulus has occurred after N-backs.

    Time frame: Baseline and at the end of each 60 days intervention period

  12. Changes of the color number correct

    The color number correct is the number of times during the N-back test that the subjects were able to correctly judge whether a repeated colour appeared or not in N rounds. A higher correct count indicates that the tester performed better in colour memory and recognition.

    Time frame: Baseline and at the end of each 60 days intervention period

  13. Changes of the color percentage correct

    Changes of color percentage correct is is the subjects' accuracy in colour-related tasks during the N-back test, expressed as a percentage. It is calculated as (number of colours correct ÷ total number of colour stimuli) × 100%. A high rate of correctness indicates that the subjects' accuracy in colour memory is high.

    Time frame: Baseline and at the end of each 60 days intervention period

  14. Changes of the shape total number

    The shape total number is the number of all shape stimuli during the N-back test. The subjects need to remember the shape changes and judge whether a repeated shape stimulus has appeared after the N-back.

    Time frame: Baseline and at the end of each 60 days intervention period

  15. Changes of the shape number correct

    The shape number correct is the number of times during the N-back test that the subjects were able to correctly judge whether or not a repeated shape appeared in N rounds. A higher number correct indicates that the subjects performed better in shape memory and recognition.

    Time frame: Baseline and at the end of each 60 days intervention period

  16. Changes of the shape percentage correct

    Changes of shape percentage correct is the subjects' accuracy in shape-related tasks during the N-back test, expressed as a percentage. It is calculated as (number of shapes correct ÷ total number of shape stimuli) × 100%. A high rate of correctness indicates that the subjects' accuracy in shape memory is high.

    Time frame: Baseline and at the end of each 60 days intervention period

  17. Changes of proteins in serum

    Collect peripheral venous blood, extract the serum, and identify the proteins of serum samples using 4D-label free technology.

    Time frame: Baseline and at the end of each 60 days intervention period

  18. Changes in biomarkers identified from other omics

    Collect peripheral venous blood, exhaled breath condensate, urine, saliva, oral cells, oral swabs, nasal swabs, skin swabs, nails and feces samples, then identify the biomarkers by conducting transcriptomic, microbiome analyses, etc.

    Time frame: Through study completion, up to 10 years

  19. Changes in other targeted biomarkers of interest

    Collect peripheral venous blood, exhaled breath condensate, urine, saliva, oral cells, oral swabs, nasal swabs, skin swabs, nails and feces samples, then identify the other targeted biomarkers of interest.

    Time frame: Through study completion, up to 10 years

07

Study locations

1 site
  • National Institute of Environmental Health, Chinese Center for Disease Control and Prevention
    Beijing, 100021, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Dec 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Apr 8, 2021
StartActual
Apr 10, 2021
Primary completionActual
Dec 15, 2021
CompletionActual
May 15, 2022
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04835337
Lead sponsor
Tiantian Li
Responsible party
Tiantian Li (professor, Centers for Disease Control and Prevention, China) — Sponsor-investigator
First posted
Apr 8, 2021
Start date
Apr 10, 2021
Primary completion
Dec 15, 2021
Completion
May 15, 2022
Last update
Sep 24, 2024

Study contacts

Tiantian Li
study director · National Institute of Environmental Health, Chinese Center for Disease Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion